For Healthcare Professionals

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

clipboard-pencil

About the study

This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease. Patients with Cushing's disease and treated with pasireotide s.c. alone and in combination with other therapies will be monitored. For this study, each enrolled patient will be followed up for 3 years after enrollment. Patients who permanently discontinue pasireotide s.c. prior to completing the 3-year observation period will be followed up for 3 months after the last dose of pasireotide s.c.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Male or female patients aged 18 years or older with a diagnosis of Cushing's disease for whom surgery has failed or for whom surgery is not an option
  2. Patients must be treated with pasireotide s.c. started either at the first visit for this study or prior to study entry

EXCLUSION CRITERIA

  1. Patients with ectopic ACTH-dependent Cushing's syndrome
  2. Patients with adrenal Cushing's syndrome
  3. Patients with Pseudo Cushing's syndrome
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-888-669-6682

Study’s details


Contition

Cushings Disease

Age

18+

Participants needed

200

Est. Completion Date

May 2024

Treatment type

Observational


Sponsor

RECORDATI GROUP

ClinicalTrials.gov identifier

NCT02310269

Study number

CSOM230B2410

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.